ABBVIE INC. vs. Ultragenyx Pharmaceutical Inc.
ABBVIE INC. (ABBV) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| ABBV | RARE | |
|---|---|---|
| Market Cap | $439.59 billion | $2.65 billion |
| Revenue (TTM) | $64.39 billion | $717.21 million |
| Net Income (TTM) | $6.32 billion | $-585,969,000 |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | RARE | |
|---|---|---|
| P/E Ratio | 70.47 | — |
| Price / Book | -74.66 | -9.10 |
| Price / Sales | 6.83 | 3.69 |
ABBV and RARE split the valuation factors evenly.
Profitability
| ABBV | RARE | |
|---|---|---|
| Net Margin | 9.81% | -81.70% |
| Return on Equity | -107.29% | 201.36% |
ABBV and RARE split the profitability factors evenly.
Dividend
| ABBV | RARE | |
|---|---|---|
| Dividend Yield | 2.77% | — |
| Payout Ratio | 195.48 | — |
ABBV and RARE split the dividend factors evenly.
Risk & Sentiment
| ABBV | RARE | |
|---|---|---|
| Short Interest | 0.85% | 5.60% |
ABBV leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, RARE overview, RARE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.